Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, Misch M, Tabatabai G, Glas M, Schnell O, Gempt J, Denk M, Reifenberger G, Bendszus M, Wuchter P, Steinbach JP, Wick W, Platten M. Bunse L, et al. Among authors: misch m. Neurol Res Pract. 2022 May 23;4(1):20. doi: 10.1186/s42466-022-00184-x. Neurol Res Pract. 2022. PMID: 35599302 Free PMC article.
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, Dictus C, Herold-Mende C, Capper D, Unterberg A, von Deimling A, Wick W, Hartmann C. Ahmadi R, et al. Among authors: misch m. J Neurooncol. 2012 Aug;109(1):15-22. doi: 10.1007/s11060-012-0863-y. Epub 2012 Apr 19. J Neurooncol. 2012. PMID: 22528790
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: misch m. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
Glioma patients in outpatient care-optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial.
Renovanz M, Hippler M, Voss M, Wehinger J, Keßler AF, Gempt J, Nadji-Ohl M, Weiß Lucas C, Rapp M, Misch M, Coburger J, Mehlitz M, Meixensberger J, Keric N, Tabatabai G, Blettner M, Schranz M, Singer S. Renovanz M, et al. Among authors: misch m. Trials. 2020 May 27;21(1):434. doi: 10.1186/s13063-020-04321-2. Trials. 2020. PMID: 32460811 Free PMC article.
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W. Platten M, et al. Among authors: misch m. Nature. 2021 Apr;592(7854):463-468. doi: 10.1038/s41586-021-03363-z. Epub 2021 Mar 24. Nature. 2021. PMID: 33762734 Free PMC article. Clinical Trial.
The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns.
Glas M, Ballo MT, Bomzon Z, Urman N, Levi S, Lavy-Shahaf G, Jeyapalan S, Sio TT, DeRose PM, Misch M, Taillibert S, Ram Z, Hottinger AF, Easaw J, Kim CY, Mohan S, Stupp R. Glas M, et al. Among authors: misch m. Int J Radiat Oncol Biol Phys. 2022 Apr 1;112(5):1269-1278. doi: 10.1016/j.ijrobp.2021.12.152. Epub 2021 Dec 26. Int J Radiat Oncol Biol Phys. 2022. PMID: 34963556 Free article.
Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N, Krenzlin H, Kalasauskas D, Freyschlag CF, Schnell O, Misch M, von der Brelie C, Gempt J, Krigers A, Wagner A, Lange F, Mielke D, Sommer C, Brockmann MA, Meyer B, Rohde V, Vajkoczy P, Beck J, Thomé C, Ringel F. Keric N, et al. Among authors: misch m. J Neurooncol. 2024 Mar;167(1):133-144. doi: 10.1007/s11060-024-04585-7. Epub 2024 Feb 7. J Neurooncol. 2024. PMID: 38326661 Free PMC article.
Frequency and clinical associations of common mental disorders in adults with high-grade glioma-A multicenter study.
Singer S, Schranz M, Hippler M, Kuchen R, Weiß Lucas C, Meixensberger J, Fehrenbach MK, Keric N, Mitsdoerffer M, Gempt J, Coburger J, Kessler AF, Wehinger J, Misch M, Onken J, Rapp M, Voß M, Nadji-Ohl M, Mehlitz M, Tatagiba M, Tabatabai G, Renovanz M. Singer S, et al. Among authors: misch m. Cancer. 2024 Nov 17. doi: 10.1002/cncr.35653. Online ahead of print. Cancer. 2024. PMID: 39550627
Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
Wasilewski D, Onken J, Höricke P, Bukatz J, Murad S, Früh A, Shaked Z, Misch M, Kühl A, Klein O, Ehret F, Kaul D, Radbruch H, Capper D, Vajkoczy P, Horst D, Frost N, Bischoff P. Wasilewski D, et al. Among authors: misch m. J Neurooncol. 2024 Mar;167(1):155-167. doi: 10.1007/s11060-024-04590-w. Epub 2024 Feb 15. J Neurooncol. 2024. PMID: 38358406 Free PMC article.
55 results